HUMAN AMYLOID IMAGING CONFERENCE

The 16th edition of the HAI will be held in Miami, FL on January 17-19, 2024.

HAI 2024

HAI will hold its 16th Annual Edition on January 17-19, 2024 in downtown Miami, at the James L. Knight Center.

Abstract intake begins October 9 and will close October 27, 2023. Past programs, posters and abstract books are available for review on this site.

HAI will not have a room block this year as there are several hotels within one mile from the conference venue, specifically, Hyatt Regency Downtown, Courtyard Marriott, Epic Kimpton, Intercontinental, etc. View the HAI app for more practical details.

As always, we remain grateful to all our fans, supporters and sponsors, and look forward to reconnecting soon!

If you wish to receive our HAI updates, please add your contact details below.

Check our work/updates on the following platforms:

Time to Conference

Day(s)

:

Hour(s)

:

Minute(s)

:

Second(s)

OBJECTIVES

1.

Attendees will have the opportunity to review the basic, fundamental principles of amyloid and tau PET imaging, including radiochemistry and radio-tracer synthesis, PET acquisition and data processing, including application of corrections for the partial volume effect and co-registration with structural data. Particular attention will be given to the assessment of longitudinal PET data as it relates to methods of analysis and comparison to other domains of data, including structural and functional brain imaging data, and clinical and cognitive outcomes.

2.

Data analysis procedures discussed will include voxel-based and region-based approaches, masking for vulnerable regions, and choice of statistical procedures and specific use of control groups from older age groups.

3.

The concept of dichotomous versus continuous measures will continue to be extensively discussed, and the attendees should be able to characterize the advantages and disadvantages of both dichotomized and continuous variable approaches to analyses with respect to specific purposes or intended uses of the outcome.

4.

Attendees will have the opportunity to evaluate and compare amyloid and tau PET data in specific clinical and clinical research contexts, including review of typical findings in Alzheimer’s disease dementia, mild cognitive impairment due to Alzheimer’s disease, and in clinically normal individuals. These phenomena will also be related to familial forms of the disease and to non-AD processes such as fronto-temporal lobar degeneration and dementia with Lewy Bodies, and chronic traumatic encephalopathy.

HAI 2024 Executive Committee

Keith Johnson, MD, Massachusetts General Hospital
Maria Carrillo, PhD, Alzheimer’s Association
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Gothenburg
Beth Mormino, PhD, Stanford University
Julie Price, PhD, Massachusetts General Hospital

HAI 2024 Theme Co-chairs

Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
Tobey Betthauser, PhD, University of Wisconsin
Anne Cohen, PhD, University of Pittsburgh
Brad Christian, PhD, University of Wisconsin
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Ansel Hillmer, PhD, Yale University School of Medicine
Milos Ikonomovic, MD, University of Pittsburgh
Heidi Jacobs, PhD, Massachusetts General Hospital
Thomas Karikari, PhD, University of Pittsburgh
Susan Landau, PhD, University of California, Berkeley
Laetitia Lemoine, PhD, Invicro
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco
Pedro Rosa-Neto, PhD, McGill University
Suzanne Schindler, MD, PhD, Washington University in St Louis
Henrik Zetterberg, MD, University of Gothenburg

HAI 2024 Young Investigator Award Judges

Hartmuth Kolb, PhD, Janssen R&D
Michael Pontecorvo, PhD, Avid Radiopharmaceuticals
Christopher Rowe, PhD, Austin Health
John Seibyl, PhD, Invicro

HAI 2024 PROGRAM COMMITTEE

Suzanne Baker, PhD, Lawrence Berkeley National Laboratory
Olivier Barret, PhD, CEA / University Paris-Saclay
Tobey Betthauser, PhD, University of Wisconsin
Brad Christian, PhD, University of Wisconsin
Anne Cohen, PhD, University of Pittsburgh
Teresa Gomez-Isla, MD, Massachusetts General Hospital
Roger Gunn, PhD, Imperial College
Ansel Hillmer, PhD, Yale University
Kenji Ishii, MD, Tokyo Metropolitan Inst. of Gerontology
Milos Ikonomovic, MD, University of Pittsburgh
Clifford R. Jack, MD, Mayo Clinic
Heidi Jacobs, PhD, Massachusetts General Hospital
Robert A. Koeppe, PhD, University of Michigan
Renaud La Joie, PhD, University of California, San Francisco
Susan Landau, PhD, University of California, Berkeley
Laetitia Lemoine, PhD, Invicro
Beth Mormino, PhD, Stanford University
Melissa Murray, PhD, Mayo Clinic
Pedro Rosa-Neto, MD, PhD, McGill University
Agneta Nordberg, MD, PhD, Karolinska Institute
Rik Ossenkoppele, PhD, VU University Medical Center
Julie Ottoy, PhD, University of Toronto
Julie Price, PhD, Harvard Medical School
Gil Rabinovici, MD, University of California, San Francisco
Susan Resnick, PhD, National Institute on Aging
Stephen Salloway, MD, Brown University
Sandra Sanabria, PhD, Genentech
Suzanne Schindler, MD, PhD, Washington University in St Louis
Christopher Schwarz, PhD, Mayo Clinic
Les Shaw, PhD, Perelman School of Medicine
Reisa Sperling, MD, Brigham and Women’s Hospital
Rik Vandenberghe, MD, PhD, KU Leuven
Victor Villemagne, MD, The University of Melbourne
Sylvia Villeneuve, PhD, McGill University
Henrik Zetterberg, MD, University of Gothenburg